References
- American Psychiatric Association., American Psychiatric Association. DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed ed. Washington, D.C: American Psychiatric Association; 2013.
- Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190:402–409.
- Polanczyk GV, Salum GA, Sugaya LS, et al. Annual research review: A meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry. 2015 Mar;56(3):345–365.
- Danielson ML, Bitsko RH, Ghandour RM, et al. Prevalence of parent-reported ADHD diagnosis and associated treatment among U.S. Children and adolescents, 2016. J Clin Child Adolesc Psychol. 2018;47(2):199–212. Mar-Apr;.
- Harpin VA. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child. 2005 Feb;90(Suppl 1):i2–7.
- Matza LS, Paramore C, Prasad M. A review of the economic burden of ADHD. Cost Eff Resour Alloc. 2005 Jun;9(3):5.
- Le HH, Hodgkins P, Postma MJ, et al. Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case. Eur Child Adolesc Psychiatry. 2014 Jul;23(7):587–598.
- Ostergaard SD, Dalsgaard S, Faraone SV, et al. Teenage Parenthood and Birth Rates for Individuals With and Without Attention-Deficit/Hyperactivity Disorder: A Nationwide Cohort Study. J Am Acad Child Adolesc Psychiatry. 2017 Jul;56(7):578–584 e3.
- Reale L, Bartoli B, Cartabia M, et al. Comorbidity prevalence and treatment outcome in children and adolescents with ADHD. Eur Child Adolesc Psychiatry. 2017 Dec;26(12):1443–1457.
- Mohammadi MR, Zarafshan H, Khaleghi A, et al. Prevalence of ADHD and its comorbidities in a population-based sample. J Atten Disord. 2019;13:1087054719886372.
- Fayyad J, Sampson NA, Hwang I, et al. The descriptive epidemiology of DSM-IV adult ADHD in the World Health Organization World Mental Health Surveys. Atten Defic Hyperact Disord. 2017 Mar;9(1):47–65.
- van Emmerik-van Oortmerssen K, van de Glind G, van den Brink W, et al. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis. Drug Alcohol Depend. 2012 Apr 1;122(1–2):11–19.
- Goode AP, Coeytaux RR, Maslow GR, et al. Nonpharmacologic Treatments for Attention-Deficit/Hyperactivity Disorder: A Systematic Review. Pediatrics. 2018;141:6.
- Rowles BM, Findling RL. Review of pharmacotherapy options for the treatment of attention-deficit/hyperactivity disorder (ADHD) and ADHD-like symptoms in children and adolescents with developmental disorders. Dev Disabil Res Rev. 2010;16(3):273–282.
- Lopez PL, Torrente FM, Ciapponi A, et al. Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2018 Mar;23(3):CD010840.
- Lieneman CC, Brabson LA, Highlander A, et al. Parent-Child Interaction Therapy: current perspectives. Psychol Res Behav Manag. 2017;10:239–256.
- Sibley MH, Graziano PA, Kuriyan AB, et al. Parent-teen behavior therapy + motivational interviewing for adolescents with ADHD. J Consult Clin Psychol. 2016 Aug;84(8):699–712.
- Bikic A, Reichow B, McCauley SA, et al. Meta-analysis of organizational skills interventions for children and adolescents with Attention-Deficit/Hyperactivity Disorder. Clin Psychol Rev. 2017;52:108–123.
- Wolraich ML, Chan E, Froehlich T, et al. ADHD diagnosis and treatment guidelines: a historical perspective. Pediatrics 2019 Oct;144(4):e20191682.
- Barbaresi WJ, Campbell L, Diekroger EA, et al. Society for Developmental and Behavioral Pediatrics Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents with Complex Attention-Deficit/Hyperactivity Disorder. J Dev Behav Pediatr. 2020;41(Suppl 2S):S35–S57. Feb/Mar.
- Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007 Jul;46(7):894–921.
- Heal DJ, Cheetham SC, Smith SL. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. Neuropharmacology. 2009 Dec;57(7–8):608–618.
- Sallee FR, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009 Feb;48(2):155–165.
- Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002 Nov;159(11):1896–1901.
- Jain R, Segal S, Kollins SH, et al. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011 Feb;50(2):171–179.
- Description Tenex (guanfacine hydrochloride) is a centrally acting antihypertensive with α2-adrenoceptor agonist properties in tablet form for oral administration. [cited 2020 Aug 23. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019032s021lbl.pdf
- Catapres®(clonidine hydrochloride, USP) Oral Antihypertensive Tablets of 0.1, 0.2 and 0.3 mg. [cited 2020 Aug 23. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/017407s037lbl.pdf
- Stein MA, Szumowski E, Blondis TA, et al. Adaptive skills dysfunction in ADD and ADHD children. J Child Psychol Psychiatry. 1995 May;36(4):663–670.
- Frank E, Ozon C, Nair V, et al. Examining why patients with attention-deficit/hyperactivity disorder lack adherence to medication over the long term: a review and analysis. J Clin Psychiatry. 2015 Nov;76(11):e1459–68.
- Clavenna A, Bonati M. Pediatric pharmacoepidemiology - safety and effectiveness of medicines for ADHD. Expert Opin Drug Saf. 2017 Dec;16(12):1335–1345.
- Jahromi LB, Kasari CL, McCracken JT, et al. Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. J Autism Dev Disord. 2009 Mar;39(3):395–404.
- Benson K, Flory K, Humphreys KL, et al. Misuse of stimulant medication among college students: a comprehensive review and meta-analysis. Clin Child Fam Psychol Rev. 2015 Mar;18(1):50–76.
- Ahmed R, Borst J, Wei YC, et al. Parents’ Perspectives About Factors Influencing Adherence to Pharmacotherapy for ADHD. J Atten Disord. 2017 Jan;21(2):91–99.
- Swanson J. Patterns and Predictors of Stimulant Medication Use from Childhood to Adulthood in the Prospective Long-Term Follow-Up of The Multimodal Treatment Study of Adhd (MTA). J Am Acad Child Adolesc Psychiatry. 2019;58(11):S313.
- Table 1.3A – types of Illicit Drug Use in Lifetime, Past Year, and Past Month among Persons Aged 18 or Older: numbers in Thousands, 2017 and 2018 [cited 2020 May 10. Available from: https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHDetailedTabs2018R2/NSDUHDetTabsSect1pe2018.htm
- Cassidy TA, Varughese S, Russo L, et al. Nonmedical Use and Diversion of ADHD Stimulants Among U.S. Adults Ages 18-49: A National Internet Survey. J Atten Disord. 2015 Jul;19(7):630–640.
- Steingard R, Taskiran S, Connor DF, et al. New Formulations of Stimulants: an Update for Clinicians. J Child Adolesc Psychopharmacol. 2019 Jun;29(5):324–339.
- Stuckelman ZD, Mulqueen JM, Ferracioli-Oda E, et al. Risk of Irritability With Psychostimulant Treatment in Children With ADHD: A Meta-Analysis. J Clin Psychiatry. 2017 Jun;78(6):e648–e655.
- Faraone SV, Biederman J, Morley CP, et al. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry. 2008 Sep;47(9):994–1009.
- Banaschewski T, Johnson M, Nagy P, et al. Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. CNS Drugs. 2018 May;32(5):455–467.
- Greenhill LL, Swanson JM, Hechtman L, et al. Trajectories of Growth Associated With Long-Term Stimulant Medication in the Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 2020 Aug;59(8):978–989.
- Highlights of Prescribing Information. Concerta (methylphenidae HCl) Extended-Release Tablets CII. [cited 2020 Apr 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021121s038lbl.pdf
- Highlights of Prescribing Information. Adderall XR (mixed salts of a single-entity amphetamine product) extended-release capsules, for oral use, CII. cited 2020 Apr 18. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021303s034lbl.pdf
- Huss M, Dirks B, Gu J, et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD. Eur Child Adolesc Psychiatry. 2018;27(10):1283–1294. Oct.
- Highlights of Prescribing Information. INTUNIV® (guanfacine) extended-release tablets, for oral use. cited 2020 Apr 12. [cited 2019 31 August]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022037s018lbl.pdf. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022037s019lbl.pdf
- Highlights of Prescribing Information. KAPVAY® (clonidine hydrochloride) extended-release tablets, for oral use. cited 2020 Apr 12. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022331s021lbl.pdf. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022331s021lbl.pdf
- Highlights of Prescribing Information. Strattera (atomoxetine) capsules for oral use. cited 2020 Apr 18. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021411s049lbl.pdf
- Clemow DB, Walker DJ. The potential for misuse and abuse of medications in ADHD: a review. Postgrad Med. 2014 Sep;126(5):64–81.
- Faraone SV. Using Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in Youths. P T. 2009 Dec;34(12):678–694.
- ADHD Market Size Worth $24.9 Billion by 2025/CAGR: 6.4%. . Available from: https://www.grandviewresearch.com/press-release/global-attention-deficit-hyperactivity-disorder-adhd-market. cited 2020 Apr 15. Available from: https://www.grandviewresearch.com/press-release/global-attention-deficit-hyperactivity-disorder-adhd-market
- Top 25 Psychiatric Medications for 2018 cited 2020 Apr 18. Available from: https://psychcentral.com/blog/top-25-psychiatric-medications-for–2018/
- Attention Deficit Hyperactivity Disorder Market Size, Share & Trends Analysis Report By Drug Type (Stimulant, Non-stimulant), By Demographic, By Distribution Channel (Hospital & Retail Pharmacy), And Segment Forecasts, 2019-2025. cited 2020 Aug 14. Available from: https://www.grandviewresearch.com/industry-analysis/attention-deficit-hyperactivity-disorder-adhd-market
- De Crescenzo F, Cortese S, Adamo N, et al. Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review. Evid Based Ment Health. 2017 Feb;20(1):4–11.
- Antshel KM. Psychosocial interventions in attention-deficit/hyperactivity disorder: update. Child Adolesc Psychiatr Clin N Am. 2015 Jan;24(1):79–97.
- Chan E, Fogler JM, Hammerness PG. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review. JAMA. 2016 May 10;315(18):1997–2008.
- Childress A, Tran C. Current Investigational Drugs for the Treatment of Attention-Deficit/Hyperactivity Disorder. Expert Opin Investig Drugs. 2016;25(4):463–474.
- Hodgkins P, Shaw M, Coghill D, et al. Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. Eur Child Adolesc Psychiatry. 2012 Sep;21(9):477–492.
- Surman C, Vaudreuil C, Boland H, et al. L-Threonic Acid Magnesium Salt Supplementation in ADHD: an Open-Label Pilot Study. J Diet Suppl. 2020;12:1–13.
- Braeckman R, Guenther S, Mickle TC, et al. Human Abuse Potential of Oral Serdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate, Compared to Focalin XR and Phentermine in Recreational Stimulant Abusers. Poster session presented at: The American Professional Society for ADHD and Related Disorders Annual Meeting; 2019 Jan18–20; Washington, DC.
- Braeckman R, Guenther S, Mickle T, et al. Human Abuse Potential of Intranasal Serdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate, in Recreational Stimulant Abusers. Poster session presented at: The American Professional Society for ADHD and Related Disorders Annual Meeting; 2019 Jan 18–20; Washington, DC.
- Pipeline and Products. cited 2020 May 03. Available from: https://kempharm.com/pipeline-products/#kp484
- KemPharm Submits KP415 NDA to the FDA for the Treatment of ADHD. cited 2020 Apr 20]. Available from: http://investors.kempharm.com/news-releases/news-release-details/kempharm-submits-kp415-nda-fda-treatment-adhd
- KemPharm Announces Top Line Results from KP415.E01 Efficacy and Safety Trial in Children With ADHD. cited 2020 Apr 20. Available from: http://investors.kempharm.com/news-releases/news-release-details/kempharm-announces-top-line-results-kp415e01-efficacy-and-safety
- KemPharm Presents Study Highlighting Patient-Friendly Dosing Properties of KP415 at the 66th Annual American Academy of Child & Adolescent Psychiatry Meeting. cited 2020 Apr 20. Available from: http://investors.kempharm.com/news-releases/news-release-details/kempharm-presents-study-highlighting-patient-friendly-dosing
- ORADURTM Abuse-deterrent Technology. cited 2020 May 23. Available from: http://www.durect.com/platform-technologies/oradur-platform/
- Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD. cited 2020 May 23. Available from: https://clinicaltrials.gov/ct2/show/NCT02450890?cond=Adhd&cntry=TW&draw=2&rank=44
- ORADUR®-Methylphenidate ER Capsule Achieves Primary Endpoint in Phase 3 Study in ADHD in Taiwan. cited 2020 May 23. Available from: https://www.prnewswire.com/news-releases/oradur-methylphenidate-er-capsule-achieves-primary-endpoint-in-phase-3-study-in-adhd-in-taiwan-300500866.html
- The Precision Timed Release™ Platform. cited 2020 Apr 24. Available from: https://cingulatetherapeutics.com/
- Pipeline. cited 2020 Apr 24 Available from: https://cingulatetherapeutics.com/pipeline/pipeline-overview/##pipeline
- Cingulate™ Technology. cited 2020 Apr 24. Available from: https://cingulatetherapeutics.com/technology/cingulate-technology/#anchor
- Caras S, Sharpe T. Pharmacokinetics of AR19, an Immediate-Release Amphetamine Sulfate Formulation Designed to Deter Manipulation for Administration Via Nonoral Routes: bioequivalence to Reference Racemic Amphetamine Sulfate, Dose Proportionality, and Food Effect. J Child Adolesc Psychopharmacol. 2020 Mar;30(2):69–80.
- Arbor Pharmaceuticals, LLC Press Releases. cited 2020 May 13. Available from: https://arborpharma.com/news/
- Herman BK, Kando JC, King T, et al. 178 Single-Dose Pharmacokinetics of Amphetamine Extended-Release Tablet Compared with Amphetamine Extended-Release Oral Suspension. CNS Spectr. 2020 Apr;25(2):312–313.
- Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD. cited 2020 May 09. Available from: https://clinicaltrials.gov/ct2/show/NCT03834766
- Quinn D, Bode T, Incledon B, et al. A Phase-2 Pharmacokinetic Study of a Modified Release Formulation of Dextroamphetamine Following Evening Administration to Adolescents and Children with ADHD. Poster session presented at: The American Profssional Society for ADHD and Related Disorders Annual Meeting; 2016 Jan15–17; Washington, DC.
- Ironshore Pharma Announces Positive HLD100 Results From Open-Label Tolerability Study In Pediatric ADHD Patients. cited 2020 May 03. Available from: https://www.biospace.com/article/releases/ironshore-pharma-announces-positive-hld100-results-from-open-label-tolerability-study-in-pediatric-adhd-patients-/
- Product Development. cited 2020 May 09. Available from: https://www.noven.com/product-development/
- Noven Announces Positive Phase 2 Results Of Investigational D-Amphetamine Transdermal System For ADHD cited 2020 May 09. Available from: https://www.noven.com/product-development/
- Rubin J, Siner D, Baker D ADAIR: an Abuse Deterrent Oral Formulation of Immediate Release Dextro-Amphetamine Sulfate (d-amphetamine). Poster session presented at: The American Professional Society of ADHD and Related Disorders Annual meeting; 2018 Jan12–14; Washington, DC.
- Whitaker T, Kardish JA, Robertson P, et al. A Pilot Human Abuse Potential Study in Recreational Stimulant Drug Users Assessing Safety, Pharmacokinetics and Abuse Liability of Intranasally Administered Manipulated ADAIR and Dextroamphetamine. Poster session presented at: The American Professional Society for ADHD and Related Disorders Annual Meeting; 2020 Jan17–19; Washington, DC.
- Our Pipeline cited 2020 May 23. Available from: https://ensysce.com/our-pipeline
- Ensysce’s prodrug technology is a game changer in the abuse deterrent field cited 2020 May 23. Available from: https://ensysce.com/our-products
- CTx-1302 cited 2020 Apr 24. Available from: https://cingulatetherapeutics.com/pipeline/ctx–1302/
- Itoh M, Koeda T, Ohno K, et al. Effects of mazindol in two patients with Prader-Willi syndrome. Pediatr Neurol. 1995;13(4):349–351. Nov.
- Wigal TL, Newcorn JH, Handal N, et al. A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD). CNS Drugs. 2018 Mar;32(3):289–301.
- Konofal E, Zhao W, Laouenan C, et al. Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder. Drug Des Devel Ther. 2014;8:2321–2332.
- Hadler AJ. Mazindol, a new non-amphetamine anorexigenic agent. J Clin Pharmacol New Drugs. 1972;12(11): 453–458. Nov-Dec.
- Adare Pharmaceuticals and NLS Pharmaceutics collaborate to develop mazindol controlled release (CR) for the treatment of ADHD and narcolepsy cited 2020 May 17. Available from: https://nlspharma.com/wp-content/uploads/2020/01/Press-release_NLS_FINAL_Jan132020_FINAL-for-Release.pdf
- Johnson JK, Liranso T, Saylor K, et al. A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD. J Atten Disord. 2020 Jan;24(2):348–358.
- Case DE, Reeves PR. The disposition and metabolism of I.C.I. 58,834 (viloxazine) in humans. Xenobiotica. 1975;5(2): 113–129. Feb.
- SPN-812 (viloxazine hydrochloride) cited 2020 May 10. Available from: https://www.supernus.com/SPN-812-viloxazine-hydrochloride
- Viloxazine hydrochloride cited 2020 May 10. Available from: https://www.drugbank.ca/drugs/DB09185
- Pinder RM, Brogden RN, Speight TM, et al. Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs. 1977 Jun;13(6):401–421.
- Nasser A, Faison SL, Liranso T, et al. 114 An Assessment of QTc Effects With SPN-812 (Extended-Release Viloxazine) in Healthy Adults. CNS Spectr. 2020 Apr;25(2):274.
- Nasser A, Hull JT, Chowdhry FA, et al. 112 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (P302): efficacy and Safety of Extended-Release Viloxazine in Adolescents with ADHD. CNS Spectr. 2020 Apr;25(2):272–273.
- Nasser A, Hull JT, Chowdhry FA, et al. 111 Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (P301) Assessing Efficacy and Safety of Extended-Release Viloxazine in Children with ADHD. CNS Spectr. 2020 Apr;25(2):272.
- Nasser A, Hull JT, Chowdhry FA, et al. 113 Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (P303) Assessing Efficacy and Safety of Extended-Release Viloxazine in Children with ADHD. CNS Spectr. 2020 Apr;25(2):273–274.
- Evaluation of SPN-812 in Adults With Attention-Deficit/ Hyperactivity Disorder cited 2020 May 15. Available from: https://clinicaltrials.gov/ct2/show/NCT04016779?term=spn-812&draw=2&rank=2
- Supernus Announces FDA Acceptance for Review of New Drug Application for SPN-812 for the Treatment of ADHD cited 2020 May 10. Available from: https://ir.supernus.com/node/11466/pdf
- Hopkins SC, Sunkaraneni S, Skende E, et al. Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults. Clin Drug Investig. 2016 Feb;36(2):137–146.
- Koblan KS, Hopkins SC, Sarma K, et al. Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745–2752.
- Findling RL, Adler LA, Spencer TJ, et al. Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial. J Child Adolesc Psychopharmacol. 2019 Mar;29(2):80–89.
- Wigal SB, Hopkins SC, Koblan KS, et al. Efficacy and Safety of Dasotraline in Children With ADHD: A Laboratory Classroom Study. J Atten Disord. 2020 Jan;24(2):192–204.
- Sunovion Discontinues Dasotraline Program cited 2020 May 16. Available from: https://news.sunovion.com/press-releases/press-releases-details/2020/Sunovion-Discontinues-Dasotraline-Program/default.aspx
- Bymaster FP, Golembiowska K, Kowalska M, et al. Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder. Synapse. 2012 Jun;66(6):522–532.
- Wilens TE, Cutler AJ, Childress A, et al. A Pilot Study of a Novel Monoamine Triple Reuptake Inhibitor, EB-1020 SR, In the Treatment of Attention-Deficit Hyperactivity Disorder in Adult Males. Poster presented at: The Society of Biological Psychiatry 2014 Annual Meeting: 2014 May 8–10; New York, NY.
- Study Results Suggest Lower Abuse Potential for Centanafadine Compared With Stimulants Used for Adult ADHD cited 2020 May 16. Available from: https://www.ptcommunity.com/news/20141212/study-results-suggest-lower-abuse-potential-centanafadine-compared-stimulants-used
- 6 Studies found for: centanafadine | ADHD [cited 2020 May 16]. Available from: https://clinicaltrials.gov/ct2/results?cond=Adhd&term=centanafadine&cntry=&state=&city=&dist=
- 2-(4-Hydroxybenzoyl)benzoic acid cited 2020 Jun 6. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/6814
- Sasaki T, Hashimoto K, Tachibana M, et al. Tipepidine in children with attention deficit/hyperactivity disorder: a 4-week, open-label, preliminary study. Neuropsychiatr Dis Treat. 2014;10:147–151.
- Kawaura K, Honda S, Soeda F, et al. [Novel antidepressant-like action of drugs possessing GIRK channel blocking action in rats]. Yakugaku Zasshi. 2010 May;130(5):699–705.
- Soeda F, Fujieda Y, Kinoshita M, et al. Centrally acting non-narcotic antitussives prevent hyperactivity in mice: involvement of GIRK channels. Pharmacol Biochem Behav. 2016;144:26–32.
- Tipepidine in Children With Attention Deficit/Hyperactivity Disorder (AD/HD): a Double-blind, Placebo-controlled Trial cited 2020 May 16. Available from: https://clinicaltrials.gov/ct2/show/NCT02305134
- Research and Development cited 2020 Jun 6. Available from: https://www.neurocentria.com/research
- Eltoprazine cited 2020 May 16. Available from: https://www.amarantus.com/therapeutics-pipeline/therapeutics/eltoprazine
- Eltoprazine cited 2020 Jun 6. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Eltoprazine
- Amarantus Subsidiary Elto Pharma Receives Notice of Allowance Covering Use of Eltoprazine Combined with CBD to Treat Parkinson’s Disease cited 2020 May 16. Available from: https://www.amarantus.com/news/press-releases/detail/2119/amarantus-subsidiary-elto-pharma-receives-notice-of
- Manor I, Ben-Hayun R, Aharon-Peretz J, et al. A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of extended-release metadoxine in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2012 Dec;73(12):1517–1523.
- Metadoxine extended-release - Arcturus Therapeutics cited 2020 Jun 6. Available from: https://adisinsight.springer.com/drugs/800034908?userId=41881521&bpIds=3991431917&checksum=5825ab5f394a8be652b35bfde57cde4c24b04e74-1457506217070-5f1383461bb4633aecc47be95e4dd761040164f3281a994b122088778c490d784c5d0a952bbc8232ef0731706e95dfc8b28447bacaa6580f4c419dc370db77e4
- A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD (Attention Deficit/ Hyperactivity) cited 2020 May 24. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02059642?term=metadoxine&cond=adhd&draw=2&rank=5
- The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD cited 2020 May 24. Available from: https://clinicaltrials.gov/ct2/show/NCT02477748?term=metadoxine&cond=Adhd&draw=2&rank=6
- Elia J, Ungal G, Kao C, et al. Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling. Nat Commun. 2018 Jan 16;9(1):4.
- PART A: efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations cited 2020 May 24. Available from: https://clinicaltrials.gov/ct2/show/results/NCT03265119?term=aevi&draw=2&rank=2
- Ampakines® cited 2020 May 17. Available from: http://respirerx.com/wp-content/uploads/2017/07/Ampakines-Platform-Summary-Final.pdf
- Purcell R, Lynch G, Gall C, et al. Brain Vacuolation Resulting From Administration of the Type II Ampakine CX717 Is An Artifact Related to Molecular Structure and Chemical Reaction With Tissue Fixative Agents. Toxicol Sci. 2018 Apr 1;162(2):383–395.
- CX717 [cited 17 May 2020]. Available from: https://adisinsight.springer.com/drugs/800020277
- Innovation & Science Pipeline cited 2020 May 17. Available from: https://www.otsuka.co.jp/en/research-and-development/pipeline/
- 1 Study found for: opc-64005/ADHD cited 2020 May 17. Available from: https://clinicaltrials.gov/ct2/results?term=opc-64005&cond=Adhd
- Altus formulation [cited 17 May 2020]. Available from: http://altusformulation.com/intelli-products/
- ATT-377 is a two ingredient, once daily treatment for ADHD cited 2020 May 17. Available from: https://attentivetx.com/att–377
- AVK-001 - A Powerful Combination cited 2020 May 17. Available from: http://avekshan.com/avk–001/
- Source Technology Pipeline cited 2020 May 17. Available from: http://en.bcwp.co.kr/research/research5
- CB8411 cited 2020 May 18. Available from: http://cennervpharma.com/cb8411/
- CM 4612 cited 2020 May 18. Available from: https://adisinsight.springer.com/drugs/800023722
- Approaching ADHD from a New Angle cited 2020 May 18. Available from: http://curemark.com/our-work/pipeline/adhd/
- INVENT Pharmaceuticals cited 2020 May 24. Available from: http://www.inventpharma.com/about.html
- Kashiv Biosciences Pipeline. [cited 2020 May 24]. Available from: http://www.kashivsp.com/pipeline/
- KemPharm Pipeline; Products cited 2020 May 30. Available from: https://kempharm.com/pipeline-products/#kp922
- MindMed Inks Deal With Switzerland University For Rights On LSD Research cited 2020 May 23. Available from: https://www.mindmed.co/news-posts/mindmed-inks-deal-with-switzerland-university-for-rights-on-lsd-research
- Liechti ME. Modern Clinical Research on LSD. Neuropsychopharmacology. 2017 Oct;42(11):2114–2127.
- ApeT Medication cited 2020 May 17. Availablf from: http://www.apetholding.com/medication.htm
- Avekshan A New Era of ADHD Treatment cited 2020 May 30. Available from: http://avekshan.com/norbinal/
- P2D Bioscience Product Pipeline cited 2020 May 23. Available from: http://p2dinc.com/products.html
- Reviva Pharmaceuticals About Us cited 2020 May 23. Available from: http://revivapharma.com/about-us/
- Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting with FDA on Brilaroxazine for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) cited 2020 May 23. Available from: https://www.biospace.com/article/releases/reviva-pharmaceuticals-announces-successful-completion-of-pre-ind-meeting-with-fda-on-brilaroxazine-for-the-treatment-of-idiopathic-pulmonary-fibrosis-ipf-/
- Brilaroxazine [cited 2020 Jun 6]. Available from: https://www.drugbank.ca/drugs/DB09226
- Shenox Pharmaceuticals, LLC. Better medicine from good science cited 2020 May 23. Available from: http://www.shenoxpharma.com/
- Pipeline cited 2020 May 24. Available from: https://www.skbp.com/eng/pipeline/pipeline.do
- Drug Profile SKL 13865 cited 2020 May 24. Available from: https://adisinsight.springer.com/drugs/800043898
- Bio B2B TAHO Pharmaceuticals Ltd. cited 2020 May 24. Available from: https://www.taiwan-healthcare.org/biotech/companies-profile?vendorSysid=BhsVendorProfile20161122141852702304979
- Proven technology for transdermal patches and oral thin films cited 2020 May 24. Available from: https://assets.zapnito.com/users/61243/documents/21476/TAHO%20Pharmaceuticals%20November%202017.pdf
- DD Therapeutics Industry: nanoparticle-based drug delivery cited 2020 May 24. Available from: https://gra.org/company/168/DD_Therapeutics.html
- Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001 Aug;23(8):1296–1310.
- Sadek B, Saad A, Sadeq A, et al. Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases. Behav Brain Res. 2016 Oct 1;312:415–430.
- Childress A, Sallee FR. Pozanicline for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Investig Drugs. 2014 Nov;23(11):1585–1593.
- Dupont RL, Coleman JJ, Bucher RH, et al. Characteristics and motives of college students who engage in nonmedical use of methylphenidate. Am J Addict. 2008;17(3):167–171. May-Jun.
- Teter CJ, McCabe SE, Boyd CJ, et al. Illicit methylphenidate use in an undergraduate student sample: prevalence and risk factors. Pharmacotherapy. 2003 May;23(5):609–617.
- Highlights of Prescribing Information VYVANSE ® (lisdexamfetamine dimesylate) capsules, for oral use, CII. [cited 30 Aug 2020]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021977s034,208510s002lbl.pdf
- Weiss MD, Childress AC, Donnelly GAE. Efficacy and Safety of PRC-063, Extended-Release Multilayer Methylphenidate in Adults with ADHD Including 6-Month Open-Label Extension. J Atten Disord. 2020 Jan;9:1087054719896853.
- Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2008 Jan;47(1):21–31.